Secukinumab Wins in Psoriatic Arthritis Save
Mease and colleagues have published their results of a phase 3 trial of secukinumab (anti-IL-17A Mab) in 606 patients with psoriatic arthritis (PsA).
Patients were given either placebo or IV secukinumab at weeks 0, 2, and 4, followed by either subcutaneous secukinumab (150 mg or 75 mg every 4 weeks) or placebo. Depending on clinical responses, placebo patients could cross over to receive subcutaneous secukinumab (150 mg or 75 mg). After 24 weeks, ACR20 responses were significiantly higher with secukinumab at 150 mg (50.0%) and 75 mg (50.5%) compared to those receiving placebo (17.3%) (P0.001).
Infections, including candida, were more common in the secukinumab group. Also, four patients in the secukinumab groups had a stroke and two with a myocardial infarction, compared with none on placebo.
Targeting IL-17A with secukinumab is effective in PsA.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.